Patents by Inventor Wenchen Zhu

Wenchen Zhu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Highly glycosylated human blood-clotting factor VIII fusion protein, and manufacturing method and application of same
    Patent number: 11471513
    Abstract: A highly glycosylated human blood-clotting factor VIII (FVIII) fusion protein, and a manufacturing method and application of same. The fusion protein comprises, from the N-terminus to the C-terminus, a human (FVIII), a flexible peptide connector, at least one rigid unit of a human chorionic gonadotropin ?-subunit carboxyl terminal peptide, and a half-life extending portion (preferentially selected from a human IgG Fc variant). The fusion protein has a similar level of biological activity as a recombinant (FVIII) and an extended in vivo half-life, thereby improving pharmacokinetics and drug efficacy.
    Type: Grant
    Filed: November 16, 2016
    Date of Patent: October 18, 2022
    Assignees: Ampsource Biopharma Shanghai Inc., Furen Pharmaceutical Group Co., Ltd, Pharmab, Inc., Kaifeng Pharmaceutical (Group) Co., Ltd.
    Inventors: Qiang Li, Wenchen Zhu, Yuanli Li, Chenggong Zhu, Yongjuan Gao, Zijia Ren, Luyan Zhu, Naichao Sun, Xiaoshan Wang, Bin Liu, Zhi Li, Wenwen Wang, Ming Jiang, Qilei Wang, Lirui Wang, Shuya Wang, Songlin Zhu, Jie Gao, Hongsheng Su
  • HIGHLY GLYCOSYLATED HUMAN BLOOD-CLOTTING FACTOR VIII FUSION PROTEIN, AND MANUFACTURING METHOD AND APPLICATION OF SAME
    Publication number: 20190365867
    Abstract: A highly glycosylated human blood-clotting factor VIII (FVIII) fusion protein, and a manufacturing method and application of same. The fusion protein comprises, from the N-terminus to the C-terminus, a human (FVIII), a flexible peptide connector, at least one rigid unit of a human chorionic gonadotropin ?-subunit carboxyl terminal peptide, and a half-life extending portion (preferentially selected from a human IgG Fc variant). The fusion protein has a similar level of biological activity as a recombinant (FVIII) and an extended in vivo half-life, thereby improving pharmacokinetics and drug efficacy.
    Type: Application
    Filed: November 16, 2016
    Publication date: December 5, 2019
    Inventors: Qiang LI, Wenchen ZHU, Yuanli LI, Chenggong ZHU, Yongjuan GAO, Zijia REN, Luyan ZHU, Naichao SUN, Xiaoshan WANG, Bin LIU, Zhi LI, Wenwen WANG, Ming JIANG, Qilei WANG, Lirui WANG, Shuya WANG, Songlin ZHU, Jie GAO, Hongsheng SU
  • ENT-kaurene diterpene compound and its derivatives, their preparation and their use
    Patent number: 8084430
    Abstract: Novel ent-kaurene diterpene compound and its derivatives, their preparation methods and their use. ent-Kaurene diterpene in the present invention could be used as desired intermediates for preparing asymmetric organic compounds and medicaments, and could be used as antitumor agent, anti-inflammatory agent and immune agent etc. The said ent-kaurene diterpene compound could be condensed with hydroxyl compounds to obtain various acetal derivatives, could be reacted with amine compounds to obtain various amino derivatives, and could be reacted with acyl halide or acid anhydride to obtain various acyl derivatives.
    Type: Grant
    Filed: January 18, 2007
    Date of Patent: December 27, 2011
    Assignees: Zhengzhou University, Furen Pharmaceutical
    Inventors: Hongmin Liu, Wenchen Zhu, Chenggong Zhu, Qingduan Wang, Yu Ke, Zhengzhou Liu, Xuebin Yan, Zhang Jianye, Hongli Qu
  • NOVEL ENT-KAURENE DITERPENE COMPOUND AND ITS DERIVATIVES, THEIR PREPARATION AND THEIR USE
    Publication number: 20100228014
    Abstract: Novel ent-kaurene diterpene compound and its derivatives, their preparation methods and their use. ent-Kaurene diterpene in the present invention could be used as desired intermediates for preparing asymmetric organic compounds and medicaments, and could be used as antitumor agent, anti-inflammatory agent and immune agent etc. The said ent-kaurene diterpene compound could be condensed with hydroxyl compounds to obtain various acetal derivatives, could be reacted with amine compounds to obtain various amino derivatives, and could be reacted with acyl halide or acid anhydride to obtain various acyl derivatives.
    Type: Application
    Filed: January 18, 2007
    Publication date: September 9, 2010
    Applicant: Zhengzhou University
    Inventors: Hongmin Liu, Wenchen Zhu, Chenggong Zhu, Qingduan Wang, Yu Ke, Zhengzhou Kiu, Xuebin Yan, Zhang Jianye, Hongli Qu